The Index
400 dossiers
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
| "The platform pioneered AI drug discovery and was real; the public-market vehicle and the unit economics were not — a £1.5bn SPAC that destroyed ~96% of value and was taken private by its founders at a ~€40-57m carcass. UNINVESTABLE as a public name (delisted); WATCH only as a private/strategic-acquisition tell for the ai-bio thesis. The lesson, not the ticker, is the asset." | — | 8 |